This is a monoinstitutional prospective pilot study, aiming to evaluate treatment-related toxicity of an hypofractionated postoperative salvage radiotherapy with daily-adaptive modality in patients affected by prostate cancer biochemical recurrence.

Patients will be treated with postoperative hypofractionated salvage radiotherapy with a dose of 59 Gy in 20 fractions with daily-adaptive modality. Considering the consolidate role and clinical outcome of postoperative hypofractionated radiotherapy with elevate level of evidence (8-10), the study will not be controlled, but compared with literature data.

Inclusion Criteria:

• Age ≤ 80 years;
• Prostate cancer diagnosis, pT2-3 pN0, any resection margin (R0 or R1);
• Indication to local salvage treatment defined as: early salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA <0.2 ng/ml or salvage radiotherapy after primary prostate surgery (radical prostatectomy) with PSA ≥0.2 ng/ml;
• No distant metastases (M0) diagnosed with PSMA-PET-CT;
• Informed consent to trial's participation and personal data treatment.

Exclusion Criteria:

• Age <18 years old;
• Adjuvant radiotherapy;
• Previous radiation in the same anatomical site.